Literature DB >> 7488895

Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen. Dutch Study Group on Prevention of Neonatal Hepatitis.

P M Grosheide1, J W Wladimiroff, R A Heijtink, J A Mazel, G C Christiaens, A S Nuijten, S W Schalm.   

Abstract

OBJECTIVE: To develop a low cost, high compliance screening programme for identification of carriers of hepatitis B surface antigen in the obstetric population of the Netherlands.
DESIGN: A seven year open, descriptive study of screening for hepatitis B surface antigen as part of routine prenatal laboratory testing at 14 weeks of gestation. Compliance with programme evaluated by checking delivery records (hospitals) or registration of births in the 30 participating municipalities (rural area).
SETTING: Three large city hospitals (two tertiary referral centres) and one rural area with a large number of home deliveries.
SUBJECTS: 99,706 pregnant women applying for prenatal care for the first time. MAIN OUTCOME MEASURES: Proportion of pregnant women routinely screened; prevalence of hepatitis B surface antigen in large cities and rural area.
RESULTS: Uptake of screening reached 97% in the hospitals after inclusion of 10% screened at delivery; the estimated uptake in the rural area was > 95%. Prevalence of hepatitis B surface antigen was 1.6% in the large cities and 0.3% in the rural area. For screening at delivery the prevalence was 2.5 times higher (4%, P < 0.01) than for screening at week 14 of gestation.
CONCLUSION: Incorporation of universal testing for hepatitis B surface antigen into routine prenatal laboratory testing is practical; high compliance is achieved when screening is supplemented with rapid screening at delivery for those who escaped routine prenatal care.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488895      PMCID: PMC2551116          DOI: 10.1136/bmj.311.7014.1197

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  14 in total

1.  Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).

Authors:  P Maupas; J P Chiron; F Barin; P Coursaget; A Goudeau; J Perrin; F Denis; I D Mar
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

2.  Cost-effectiveness of prenatal screening and immunization for hepatitis B virus.

Authors:  J A Arevalo; A E Washington
Journal:  JAMA       Date:  1988-01-15       Impact factor: 56.272

3.  Worldwide control of hepatitis B virus: an approaching reality?

Authors:  D P Francis
Journal:  Pediatrics       Date:  1985-11       Impact factor: 7.124

4.  Combined passive and active immunization for preventing perinatal transmission of hepatitis B virus carrier state.

Authors:  H Tada; M Yanagida; J Mishina; T Fujii; K Baba; S Ishikawa; S Aihara; F Tsuda; Y Miyakawa; M Mayumi
Journal:  Pediatrics       Date:  1982-10       Impact factor: 7.124

5.  Failure of Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population.

Authors:  M M Jonas; E R Schiff; M J O'Sullivan; M de Medina; K R Reddy; L J Jeffers; T Fayne; K C Roach; B W Steele
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

6.  Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA.

Authors:  H M Ip; P N Lelie; V C Wong; M C Kuhns; H W Reesink
Journal:  Lancet       Date:  1989-02-25       Impact factor: 79.321

7.  Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations.

Authors:  J A Mazel; S W Schalm; B C de Gast; A S Nuijten; R A Heijtink; M J Botman; J R Bänffer; L J Gerards; J Zwijnenberg; J Mettau
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

8.  Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen.

Authors:  S W Schalm; J A Mazel; G C de Gast; R A Heijtink; M J Botman; J R Bänffer; L J Cerards; J Zwijnenberg; W P Fetter; S M Nuijten
Journal:  Pediatrics       Date:  1989-06       Impact factor: 7.124

9.  Prevalence of hepatitis B virus infection in Tonga: identifying high risk groups for immunization with hepatitis B vaccine.

Authors:  R B Wainwright; B J McMahon; T R Bender; W L Heyward; S Nakanishi; K Y Wainwright; S Foliaki; S L Erickson; H A Fields
Journal:  Int J Epidemiol       Date:  1986-12       Impact factor: 7.196

10.  Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial.

Authors:  R P Beasley; L Y Hwang; C E Stevens; C C Lin; F J Hsieh; K Y Wang; T S Sun; W Szmuness
Journal:  Hepatology       Date:  1983 Mar-Apr       Impact factor: 17.425

View more
  6 in total

1.  Antenatal screening for carriers of hepatitis B virus.

Authors:  E H Boxall
Journal:  BMJ       Date:  1995-11-04

2.  Hepatitis B in the Chinese community in Britain.

Authors:  K Y Tang; T Chan; K A Fenton; R J Gilson
Journal:  BMJ       Date:  1996-02-24

3.  Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women from Eastern Turkey.

Authors:  Esra Çınar Tanrıverdi; Zülal Özkurt; Berrin Göktuğ Kadıoğlu; Handan Alay; Okşan Çalıkoğlu; Özlem Koca; Zeynep Kamalak
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

4.  Prevalence and correlates of HIV, syphilis, and hepatitis knowledge among intrapartum patients and health care providers in Kabul, Afghanistan.

Authors:  C S Todd; M Ahmadzai; F Atiqzai; J M Smith; S Miller; P Azfar; H Siddiqui; S A S Ghazanfar; S A Strathdee
Journal:  AIDS Care       Date:  2009-01

5.  Low rates of hepatitis B virus screening at the onset of chemotherapy.

Authors:  Jessica P Hwang; Michael J Fisch; Hong Zhang; Michael A Kallen; Mark J Routbort; Lincy S Lal; John M Vierling; Maria E Suarez-Almazor
Journal:  J Oncol Pract       Date:  2012-06-12       Impact factor: 3.840

6.  The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions.

Authors:  Jördis J Ott; Gretchen A Stevens; Steven T Wiersma
Journal:  BMC Infect Dis       Date:  2012-06-09       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.